Gene · 970
Papers4,349
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
1,501 to 1,520 of 4,349
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Genetic Therapy and Molecular Targeted Therapy in Oncology: Safety, Pharmacovigilance, and Perspectives for Research and Clinical Practice. | Int J Mol Sci | 2022 | 35328435 | PubTator, text mining | PubMed |
| Cytokine-Induced Senescence in the Tumor Microenvironment and Its Effects on Anti-Tumor Immune Responses. | Cancers (Basel) | 2022 | 35326515 | PubTator, text mining | PubMed |
| T Cells, Interleukin-2 and Systemic Lupus Erythematosus-From Pathophysiology to Therapy. | Cells | 2022 | 35326431 | PubTator, text mining | PubMed |
| Advances in COVID-19 mRNA vaccine development. | Signal Transduct Target Ther | 2022 | 35322018 | PubTator, text mining | PubMed |
| New Approaches to Myelodysplastic Syndrome Treatment. | Curr Treat Options Oncol | 2022 | 35320468 | PubTator, text mining | PubMed |
| A novel TanCAR targeting IL13Rα2 and EphA2 for enhanced glioblastoma therapy. | Mol Ther Oncolytics | 2022 | 35317513 | PubTator, text mining | PubMed |
| Non-GCB Diffuse Large B-Cell Lymphoma With an Atypical Disease Course: A Case Report and Clinical Exome Analysis. | World J Oncol | 2022 | 35317330 | PubTator, text mining | PubMed |
| Multi-omics landscape and clinical significance of a SMAD4-driven immune signature: Implications for risk stratification and frontline therapies in pancreatic cancer. | Comput Struct Biotechnol J | 2022 | 35317237 | PubTator, text mining | PubMed |
| MYBL2 is a Novel Independent Prognostic Biomarker and Correlated with Immune Infiltrates in Prostate Cancer. | Int J Gen Med | 2022 | 35313552 | PubTator, text mining | PubMed |
| DNA Methylation of T Lymphocytes as a Therapeutic Target: Implications for Rheumatoid Arthritis Etiology. | Front Immunol | 2022 | 35309322 | PubTator, text mining | PubMed |
| 5-Methylcytosine Related LncRNAs Reveal Immune Characteristics, Predict Prognosis and Oncology Treatment Outcome in Lower-Grade Gliomas. | Front Immunol | 2022 | 35309316 | PubTator, text mining | PubMed |
| Altered pathways and targeted therapy in double hit lymphoma. | J Hematol Oncol | 2022 | 35303910 | PubTator, text mining | PubMed |
| Cancer vaccines as promising immuno-therapeutics: platforms and current progress. | J Hematol Oncol | 2022 | 35303904 | PubTator, text mining | PubMed |
| Interactions of circRNAs with methylation: An important aspect of circRNA biogenesis and function (Review). | Mol Med Rep | 2022 | 35302170 | PubTator, text mining | PubMed |
| Improving CAR-T immunotherapy: Overcoming the challenges of T cell exhaustion. | EBioMedicine | 2022 | 35301179 | PubTator, text mining | PubMed |
| Gene Expression of CD70 and CD27 Is Increased in Alopecia Areata Lesions and Associated with Disease Severity and Activity. | Dermatol Res Pract | 2022 | 35300124 | PubTator, text mining | PubMed |
| Development and Validation of a Ferroptosis-Related lncRNAs Prognosis Model in Oral Squamous Cell Carcinoma. | Front Genet | 2022 | 35299954 | PubTator, text mining | PubMed |
| A genome-scale screen for synthetic drivers of T cell proliferation. | Nature | 2022 | 35296855 | PubTator, text mining | PubMed |
| Cancer cell-intrinsic resistance to BiTE therapy is mediated by loss of CD58 costimulation and modulation of the extrinsic apoptotic pathway. | J Immunother Cancer | 2022 | 35296559 | PubTator, text mining | PubMed |
| Preclinical Development and Evaluation of Allogeneic CAR T Cells Targeting CD70 for the Treatment of Renal Cell Carcinoma. | Cancer Res | 2022 | 35294525 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/970/papers?page=76